Skip to main navigation

Topbar Nav

  • Investor Relations Home
  • Careers
  • Connect

Home

Main navigation

 

Main navigation

  • News & Events
    • Press Releases
    • Events & Presentations
    • Publications
    • Media Materials
  • Stock Information
    • Analyst Coverage
    • Shareholder Fraud Warning
    • Annual General Meeting
    • Information on dividend
    • Share Repurchase Program
  • Corporate Governance
    • ESG
    • Transparency
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Financial Calendar
  • IR Resources
    • Investor FAQs
    • Sign-up for Email Alerts

Topbar Nav

  • Investor Relations Home
  • Careers
  • Connect
  • Quarterly Reports

    Investor Contact Sylke Maas, Ph.D.
    Vice President Investor Relations & Strategy
    Send Email
    +49 6131 9084-0
    For U.S. Investors:
    Westwicke
    John Woolford
    Send Email
    +1 443 213-0506
    Media Contact Jasmina Alatovic
    Vice President External Communications
    Send Email
    +49 6131 9084-0
    • English
    • German

    Quarterly Reports

    Show all

    2022

    Q1
    • Q1 2022 Press Release
    • Q1 2022 Presentation 2.1 MB
    • Q1 2022 Webcast Recording
    • Q1 2022 Financial Report 9.3 MB
    Q2
    • Q2 2022 Press Release
    • Q2 2022 Presentation 1.8 MB
    • Q2 2022 Webcast Recording
    • Q2 2022 Financial Report 10.5 MB

    2021

    Q1
    • Q1 2021 Press Release
    • Q1 2021 Presentation 2.6 MB
    • Q1 2021 Webcast Recording
    • Q1 2021 Financial Report 5.6 MB
    Q2
    • Q2 2021 Press Release
    • Q2 2021 Presentation 2.8 MB
    • Q2 2021 Webcast Recording
    • Q2 2021 Financial Report 5.6 MB
    Q3
    • Q3 2021 Press Release
    • Q3 2021 Presentation 2.5 MB
    • Q3 2021 Webcast Recording
    • Q3 2021 Financial Report 5.7 MB
    Q4
    • Q4 2021 Press Release
    • Q4 2021 Presentation 1.3 MB
    • Q4 2021 Webcast Recording

    2020

    Q1
    • Q1 2020 Financial Report 48.8 KB
    • Q1 2020 Presentation 1 MB
    • Webcast Recording
    Q2
    • Q2 2020 Financial Report 314.6 KB
    • Q2 2020 Presentation 2 MB
    • Webcast Recording
    Q3
    • Q3 2020 Financial Report
    • Q3 2020 Presentation 1.4 MB
    • Webcast Recording
    Q4
    • Full Year and Q4 2020 Financial Report 81 KB
    • Full Year and Q4 2020 Presentation 3.5 MB
    • Webcast Recording

    2019

    Q3
    • Q3 2019 Financial Report 329.1 KB
    • Q3 2019 Presentation 1.7 MB
    • Webcast Recording

    Before footer menu

    • Information Request
    • RSS Feeds
    Logo

    BioNTech SE
    An der Goldgrube 12
    55131 Mainz
    Germany

     

    T: +49 6131 9084-0

    For questions on logistics,
    handling or other issues:
    service@biontech.de

    For any other questions, please
    use our contact form at
    connect.biontech.de

    We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases

    02. Footer Column2 Links

    • Connect
    • Our DNA
    • How We Translate
    • Science
    • For Patients
    • Investors & Media
    • Careers

    03. Footer Column3 Links

    • Imprint
    • Terms Of Use
    • General Terms and Conditions
    • General Conditions Of Purchase
    • Data Privacy Statement
    • Data Processing Terms Business Partners
    • Adverse Event Reporting
    • Cookie Settings

    Follow us

       

    © Copyright BioNTech SE . All Rights Reserved.
     
    Our Vision
    Our vision: individualize cancer medicine
    Leadership
    Meet our leadership team
    Collaborators
    Get to know our partners
    Our Locations
    Learn about our services
    The BioNTech approach
    How we approach individualized cancer medicine
    mRNA Therapeutics
    Why mRNA represents a disruptive new drug class
    Antibodies
    Beyond mRNA: Expanding therapeutics with our antibody discovery engines
    Manufacturing
    Manufacturing our own therapeutics
    Pipeline
    Explore our pipeline
    Platforms
    Tour our platforms that produce individually-tailored therapeutics
    Publications
    Browse our research publications
    Info & Resources
    Our Mission: broaden the therapeutic universe to benefit patients
    Clinical trials
    Clinical trials currently ongoing